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Abstract
Background: Lertal®, an oral nutraceutical, contains extract of Perilla, quercetin, and Vitamin D3. The current polycentric,
randomized, parallel-group, controlled study aimed in the Phase II to evaluate the efficacy and safety of Lertal® in
preventing allergic rhinitis (AR) exacerbations in children after the end of the pharmacological treatment phase.
Materials and methods: One hundred twenty-eight children completed Phase II. Sixty-four children continued Lertal®
treatment (Lertal® Group: LG) and 64 ones did not assume any medication (Observation Group: OG) for 4–12weeks.
The study endpoints were the number, intensity, and duration of AR exacerbations, and the length of symptom-free time.
Results: Children of LG halved the risk (HR = 0.54) of having AR exacerbation. Children of LG had significantly (p = 0.039)
less AR exacerbations than OG children. In children with AR exacerbations, the total number of days in which each
patient took at least one rescue medication was significantly (p = 0.018) lesser in LG children than OG ones. In the global
population, the cumulative days treated with rescue medication was significantly (p< 0.0001) higher in OG than in LG.
There was no clinically relevant adverse event.
Conclusions: The present study documented that prolonged Lertal® assumption was safe and able to significantly
reduce, such as halving, the risk of AR exacerbation, their duration and the use of rescue medications, after the
suspension of the one-month antihistamine treatment. Therefore, Lertal® could be envisaged as an effective preventive
treatment in AR children able to guarantee long symptom-free time.
Trial registration: Clinical trial registration: ClinicalTrials gov ID NCT03365648.
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Background
Allergic rhinoconjunctivitis (AR) is the most common
IgE-mediated disorder [1]. Children suffering from AR
present nose (itching, sneezing, rhinorrhoea, and con-
gestion) and eye (itching, redness, lacrimation, and eye-
lid swelling) symptoms. Interestingly, AR may also affect
mood, sleep, leisure activity, and scholastic performance.
AR symptoms depend on allergic inflammation that is
characterized by a typical eosinophilic infiltrate [2].
Antiallergic drugs, antihistamines (oral or nasal) and
nasal corticosteroids, represent the standard therapy for
AR. However, these drugs may exert symptomatic relief
of symptoms without persistent improvements of allergic
disorder [3, 4]. In addition, their discontinuation is asso-
ciated with quick symptom and cellular infiltrate relapse.
It has been reported that symptoms and cellular infil-
trate reappeared after suspension of an intranasal cor-
ticosteroid treatment: respectively after 3 days for
symptoms, after 4 days for nasal neutrophils, and 6 days
for eosinophils [5]. On the other hand, aggressive ther-
apy and prolonged use of medications could induce sig-
nificant side effects in children [6]. Therefore, there is
increasing interest for new treatments for children with
AR [7]. In this regard, there is evidence that nutraceuti-
cals may be combined with standard therapy to speed
up recovery, make it long lasting, avoid aggressive thera-
peutic regimens, and potentially prevent clinical relapse
[8, 9].
Lertal® is a novel oral food supplement, containing Pe-
rilla frutescens, quercetin, and vitamin D3. The dry seed
extract of Perilla frutescens contains rosmarinic acid and
other flavonoids, such as luteolin, apigenin and chrysoer-
iol, and has shown in vivo and in vitro potential anti-al-
lergic activity [10, 11]. Quercetin tends to stabilize cell
membranes and block degranulation of mast cells and
basophils, inhibiting the release of pro-inflammatory
mediators and cytokines implicated in allergic inflamma-
tion [12, 13]. Vitamin D3 is essential for the normal
function of the immune system and may exert a role in
both prevention and potential treatment of AR, restoring
physiological T regulatory activity and exerting also anti-
inflammatory activity [14–16].
Notably, Lertal® is formulated in bilayer tablets com-
posed of a fast-release layer that allows the rapid antihis-
tamine activity of Perilla, and a sustained-release layer
that enhances Quercetin and Vitamin D3 bioavailability
and anti-allergy activity spread for long time.
Lertal® has been recently found to be able to reduce
symptom severity and medication use in adults with AR
[17]. As that study was open and conducted in adults,
two hypotheses were therefore tested in a paediatric
model of children with AR: i) the Lertal® capability to
sustain the effectiveness of antihistaminic therapy and/or
reduce its insensitivity, and ii) the Lertal® potentiality to
prevent possible relapse after antihistamine therapy sus-
pension. Therefore, a polycentric, randomized, study was
designed in two phases. The first phase was conducted
as double blind, placebo-controlled trial during standard
antihistaminic AR treatment and evaluated the efficacy
and safety of Lertal® as an add-on treatment. The ob-
tained findings demonstrated that Lertal® was able to sig-
nificantly prevent the occurrence of clinical worsening
during the active treatment and was safe in AR poly-al-
lergic children [18]. The second phase was designed as
open and parallel-group study and was conducted after
the end of the blind-period. Therefore, we currently re-
port the outcomes of the second phase of this trial.
Materials and methods
The phase II was an open-label, parallel-group, exten-
sion study in which patients treated with study product
in Period I continued treatment with Lertal® tablets,
whereas patients initially treated with placebo received
no further treatment [18]. One hundred and sixty pa-
tients suffering from AR were planned for enrolment in
17 Italian Paediatric Allergy clinics. AR diagnosis was
performed, according to validated criteria [3, 4], such as
if nasal symptom history was consistent with docu-
mented sensitization.
Inclusion criteria were: age range 6–12 years, AR diag-
nosis, sensitization to house dust mites or pollens, Total
Symptoms Score (TSS) ≥ 15 and at least 1 for nasal
congestion, written informed consent of patients and of
parents or legal guardians. Exclusion criteria were:
uncontrolled asthma, secondary rhinitis to other causes,
concomitant acute or chronic rhinosinusitis, nasal
polyps, current use of topical or systemic corticosteroids,
antihistamines, antileukotrienes, inadequate washout of
them, nasal anatomic defect, respiratory infections in the
last 2 weeks, participation in other clinical studies in the
last month, documented hypersensitivity to the study
product or its excipients, and trip planned outside of the
study area.
TSS was the sum of the total nasal symptom score
(TNSS), including itching, sneezing, rhinorrhea, nasal
congestion, plus the total ocular symptom score (TOSS),
including itching, hyperaemia of conjunctiva, tearing,
plus total throat symptom score (TTSS), including
itching and coughing. With the help of their parents,
patients scored symptoms severity on a 4-point scale:
0 = absent or irrelevant, 1 =mild, 2 =moderate, 3 = severe.
After the 4-week active treatment period, children
treated with Lertal® plus standard therapy continued to
take Lertal® tablets (1 tab/day for 4–12 weeks) alone
(such as without antihistamines), whereas children
treated with Placebo suspended any treatment. The
current treatment lasted 4 weeks in children with pollen
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allergy, whereas 12 weeks in children with perennial
allergy.
Each Lertal® tablet contains the following active ingre-
dients in a double-layer “fast-slow” release tablets: Quer-
cetin 150 mg, Perilla frutescens 80 mg (as dry extract of
the seeds containing rosmarinic acid, luteolin, apigenin
and chrysoeriol), and Vitamin D3 5 mcg (200 IU).
Treatment with systemic or intranasal corticosteroids,
leukotriene antagonists, and sodium cromoglicate were
prohibited during the study. Two visits, were scheduled
during this period to collect efficacy, safety and quality
of life data. Patients should return their diaries at these
visits in order to collect data concerning exacerbations
and or adverse events. Patients also need to return all
unused product to check compliance with treatment.
Patient-reported outcomes and diary recorded data,
including the symptom relapse, the use of rescue medi-
cation/concomitant medication and the occurrence of
adverse events, were collected at the visits. Clinical data
were reported in an electronic Case Report Form
(eCRF).
The end-points of the Phase II were the number, in-
tensity, and duration of AR exacerbations, and the
length of symptom-free time. Exacerbation was defined
as the need of restarting an antihistamine medication of
any kind, at any dose and of any duration because of
symptom recurrence.
Patients were visited at the beginning and at the end
of Phase II, such as after 4 weeks for children allergic to
pollens and 8 weeks for children allergic to mites.
Safety was assessed on the incidence of adverse events
for each treatment and on physical examinations.
The study protocol was approved by the Ethics Com-
mittees of each center. The study was registered at Clini-
calTrials.gov ID NCT03365648.
The between-group analysis was performed by means
of a t-test for independent samples or analogous non-
parametric test or a Chi-square test in contingency
tables. The Hazard Ratio (HR) was calculated by the uni-
variate Cox model and Kaplan-Meier curves were per-
formed. The time to first exacerbation was calculated as
days elapsed between the start of period II (i.e. unblind-
ing date) and the start date of the first exacerbation or
the last date of observation. In particular, a reduction in
the rate of first AR exacerbation of approximately 30%,
corresponding to a HR of 0.70, was considered clinically
relevant [19]. Missing data were substituted by worse
case method.
Results
Globally, 146 children (94 males and 52 females, aged
6–12 years, mean age 9.1 + 1.88) were randomized in
the Phase I of the study. There were 18 children who
dropped out. The Phase II study included a total of 128
patients, of which 64 assigned to open Lertal® therapy
(Lertal® Group: LG) and 64 to observation alone (Obser-
vation Group: OG).
The two groups were homogeneous as far as age, gen-
der, BMI, type of allergy, time from diagnosis and symp-
tom severity are concerned at baseline.
The LG showed a significant difference concerning the
duration of symptom-free days in comparison with OG
(Log-Rank test = 4.16; p = 0.0413) with a HR 0.54 (CI
95% 0.29–0.99), as shown in Fig. 1.
Considering the number of children who experience
an AR exacerbation, there was a significant difference
between groups as only 16 children (25%) in the LG had
an AR exacerbation, whereas 27 children (42.2%) of OG
had an AR exacerbation (p = 0.039), as shown in Fig. 2.
Analysing only the children with AR exacerbation, the
Fig. 1 Kaplan-Meyer Plot. Time to first exacerbation calculated as days elapsed between the start of Phase II (i.e. unblinding date) and the start
date of the first exacerbation or the last date of observation in Lertal® Group and Observation Group
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total number of days in which each patient took at least
one rescue medication was significantly (p = 0.018) lesser
in LG than OG (9.6 + 9 days and 28.5 + 27.2 days re-
spectively). Considering the global population, the cu-
mulative days treated with rescue medication was
significantly (p < 0.0001) higher in OG than in LG (683
days and 153 days respectively).
Analysing only children treated with concomitant
medications, LG children had tendentially less AR exac-
erbations than OG children (7 vs 12; p = 0.051).
Lertal® treatment was well tolerated and no serious ad-
verse event was reported. Out of the patients who en-
tered in Period II, 55 patients experienced one or more
adverse events (32 in LG and 23 in CG). One patient in
LG discontinued because of acute urticaria and cough
due to pollen allergy exacerbation.
Discussion
AR affects up to 40% of the general population [1], and
represents a relevant burden for the society. Adequate,
effective, and safe treatment is always recommended in
all AR patients, but with particular attention in children.
A particular aspect of allergic disorders is that medica-
tions do not cure AR, but limit to relief symptoms and
control inflammation. Notably, the results obtained by
long-term continuous anti-inflammatory treatments,
when suspended, rapidly disappear and are not able to
modify the natural history as demonstrated by an elegant
study in pre-schoolers with wheezing [20]. In fact, the
PEAK (prevention of early asthma in kids) study evi-
denced that 2-year inhaled fluticasone did not modify
the further progression of the disease.
AR is characterized by type-2 immune response that
promotes, sustains, and maintains an abundant eosino-
philic infiltrate in the nasal mucosal tissue and the on-
going production of allergen-specific IgE. The link
between the inhaled causal allergen and IgE expressed
on the surface of mast cells starts a cascade of inflamma-
tory events, mainly concerning the histamine (the pivotal
mediator in AR) release that result in symptom occur-
rence. For this reason, antihistamines and intranasal cor-
ticosteroids are the most effective and used medications
in AR patients [1, 3, 4]. However, the clinical effect of a
single dose of an antihistamine usually lasts until 24–36
h, then symptoms reappear promptly [21]. Similarly, the
duration of intranasal corticosteroids effects is very
short-lived after suspension, such as in a few days symp-
toms and inflammatory events recur [5]. In addition,
both antihistamines and intranasal corticosteroids may
be unable to completely inhibit allergic reaction in some
circumstances, such as highly allergic patients, intense
allergen exposure, interfering disorders. Therefore, the
use of add-on medications could be fruitful in such situ-
ations. Actually, the Phase I of the current study demon-
strated the Lertal® used as add-on treatment was able to
significantly reduce the symptom worsening, i.e. AR ex-
acerbation, in poly-allergic children [18]. Interestingly,
this favourable effect was evident in the second part of
the active treatment, such as between the third and the
fourth week, when some patients, after an initial re-
sponse to drug treatment, showed a symptom worsen-
ing. This preventive activity could be explained by the
anti-inflammatory, the immune-modulatory, and the
anti-allergic properties of the Perilla extract, the quer-
cetin, and the vitamin D3.
The outcomes of the Phase II not only confirm indeed
the favourable effects observed in the Phase I, but also
highlight an even more relevant preventive activity con-
sequent to the prolonged use. In particular, we would
underline two main issues. The highly favourable HR
value of 0.54: it means that the risk of AR exacerbation
had reduced in children taking Lertal® for a 4–12-week
period of 46% in comparison with children without pre-
ventive intervention after the suspension of the standard
4-week antihistamine treatment. This finding is consist-
ent with previous studies conducted in patients with
asthma and in children with allergic rhinitis. Tonelli and
colleagues demonstrated that 56% of asthmatic patients,
regularly treated with inhaled corticosteroids for at least
6 months, experienced asthma recurrence in the first
month after discontinuation of the pharmacological
therapy [22]. A randomized and placebo-controlled
study evaluated the efficacy of allergen immunotherapy
in preventing asthma exacerbations during an inhaled
corticosteroid reduction period [23]. Compared with pla-
cebo, there was a reduced risk of an exacerbation with
deterioration in asthma symptoms (HR 0.64) in the
group taking the higher dose of allergen. Another ran-
domized and placebo-controlled study investigated the
effect of allergen immunotherapy on the risk of develop-
ing asthma in a large group of children with AR [24].
Fig. 2 Percentages of children experiencing AR exacerbation in
Lertal® Group and Observation Group
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The sublingual immunotherapy reduced the risk of
experiencing asthma symptoms or using asthma medica-
tion at the end of the trial (OR = 0.66) and during the 2-
year follow-up. Notably, the primary endpoint, such as
the time to onset asthma, was not different between
groups.
Therefore, the present study provided a clinically rele-
vant results, also consisting with these studies, such as
Lertal® treatment was able to approximately halve the
risk of AR exacerbation after one-month antihistamine
treatment. This outcome is also supported by the larger
number of Lertal®-treated children (75%) who did not
experience AR exacerbation than untreated children
(58%). In addition, these findings are consistent with
outcomes documented in the Phase I that evidenced that
Lertal®, used as add-on therapy, was able to tendentially
improve the effect of the standard AR treatment and es-
pecially Lertal® significantly reduced the possible occur-
rence of intercurrent relapse during the standard
treatment in children with AR. In addition, it has been
evidenced that Lertal® was also able to significantly re-
duce the number of exacerbations, the duration, and the
use of rescue medications. Notably, the number of
symptom-free days was significantly higher in Lertal®-
treated children. This outcome has a clinical relevance
of paramount importance as it underlines the possibility
of avoiding the use of medications, mainly after a long
antihistamine course, i.e.4 weeks. This point deserves ad-
equate attention as AR cannot be cured by medications,
even though prescribed for long periods. Therefore, re-
ducing the use of pharmacological therapy is particularly
required in childhood. In addition, this outcome de-
serves also a consideration from a pharmaco-economic
point of view. Actually, a greater number of symptom-
free days means a significantly saving of medication use.
Last but not least, symptom-free condition is closely as-
sociated with a good quality of life, as it is well known
that rhinitis severity affects this aspect.
These findings may be explained by a sustained and
prolonged effect on allergic reaction depending on the
multifaceted mechanisms of action exerted by Lertal®. In
particular, Lertal® effects seem to be grounded in the
complex anti-inflammatory, immune-modulatory, and
anti-allergic activity exerted on the immune response by
the three compounds.
However, this study has some limitations, including
the lack of measurement of inflammation biomarkers
and of objective functional assessment. In addition, it
has to be noted that the Vitamin D3 supplementation
may be controversial as recently pointed out [25]. Wjst
contested the indiscriminate use of this pre-hormone in
childhood as there are no convincing evidence about its
real effectiveness. However, there are substantial data
supporting its utility in many disorders, including
childhood asthma. In this regard, Litonjua has recently
stated that evidence continues to accumulate that vita-
min D supplementation helps to prevent the develop-
ment of asthma and recurrent wheeze in early life, and
may also help in the management of asthma [26].
On the other hand, the strength of this study was the
methodological accuracy, based on the double-blinded,
randomized, parallel-group, and placebo-controlled de-
sign of the Phase I, the presence of a successive observa-
tional period (Phase II), and the sample size estimate.
Conclusions
The present study documented that prolonged Lertal®
treatment was safe and able to significantly reduce, such
as halving, the risk of AR exacerbation occurrence, their
duration, and the need of symptomatic medications in
children with allergic rhinitis. Therefore, Lertal® could be
envisaged as an effective preventive treatment in AR
children able to guarantee long symptom-free time.
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